Senaste nyheterna

• 

  9 December 2025 08:31

  Data Published in the New England Journal of Medicine Confirm the Long-term Durability and Safety of HEMGENIX® (etranacogene dezaparvovec) Over Five Years

  Global biopharma leader CSL (ASX:CSL) today announced five-year (60-month) results from the pivotal Phase 3 HOPE-B study, confirming the long-term durability and safety of a one-time infusion of HEMGENIX® (etranacogene dezaparvovec) in adults living with moderate to severe haemophilia B. Published in the New England Journal of Medicine (NEJM).

• Nya terapier kräver nya betalningsmodeller – CSL deltar vid New Horizons in Biologics & Bioprocessing i Stockholm

  4 December 2025 08:57

  Sverige ligger under EU-snittet i patienters tillgång till behandlingar för sällsynta sjukdomar och patienter i 20 europeiska länder har tillgång till fler särläkemedel. Resultatbaserade avtal där betalning kopplas till faktisk klinisk effekt kan minska ekonomiska risker och samtidigt bidra till kostnadsbesparingar och effektivare vård. Flera länder, som Danmark, har redan infört sådana modeller.

  

• Danmark: Først blandt de nordiske lande til at tilbyde Andembry® – CSL Behrings nye forebyggende behandling til hereditært angioødem (HAE)

  5 November 2025 09:02

  Andembry® repræsenterer et væsentligt fremskridt indenfor behandling af HAE; med Danmark som det første land i Norden, hvor Andembry® er tilgængeligt og tilbydes som en ny mulighed til forebyggende behandling. Andembry® er det første og eneste faktor XIIa-hæmmende monoklonale antistof (anti-FXIIa mAb), med subkutan dosering én gang om måneden fra behandlingsstart.

  

• CSL Behring’s Gene Therapy HEMGENIX (etranacogene dezaparvovec): Four Years Post-Infusion Data Continue to Show Sustained Efficacy and Safety in Adults with Haemophilia B

  11 Februari 2025 08:34

  94% of patients eliminated factor IX prophylaxis and remained free of continuous prophylaxis through four years post-treatment. Mean factor IX activity levels were sustained at near normal levels of 37% through four years post-treatment, reinforcing the efficacy of HEMGENIX® in the treatment of haemophilia B.

  

• CSL Behring Appoints Helena Bragd as New General Manager for the Nordic Region

  28 Januari 2025 08:31

  Helena Bragd is the new General Manager of CSL Behring Nordic Region – Sweden, Denmark, Norway, Finland, and Iceland. CSL Behring is a global biotherapeutics leader driven by our promise to save lives.

  

• First patients treated with HEMGENIX® (etranacogene dezaparvovec) gene therapy for haemophilia B in Denmark

  21 Januari 2025 08:26

  CSL Behring Denmark today announced that the first Danish patients with haemophilia B were treated with the gene therapy HEMGENIX® (etranacogene dezaparvovec). HEMGENIX® is the first one-time gene therapy to be approved in Europe for the treatment of adults with severe and moderately severe haemophilia B.

  

• CSL Behring Signs Milestone Commercial Agreement with Amgros to Fund Haemophilia B Gene Therapy HEMGENIX in Denmark

  29 Oktober 2024 09:34

  CSL Behring today announced that an outcome-based agreement has been reached with Amgros, the Danish procurement authority, for the national reimbursement of HEMGENIX® in Denmark. Denmark is the first country in the Nordic region to reimburse HEMGENIX® under such a performance-based model, in which the regions only incur costs if the gene therapy proves effective over an agreed long-term period.

  

Kontakter

• 

  Fredrik Sjöö, MD, PhD

  Presskontakt Head of Medical Affairs Nordic Region Talesperson för medicinska frågor CSL Behring Norden. fredrik.sjoeoe@cslbehring.com +46 (0)8 544 966 85